Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disease, also regarded as “type 3 diabetes” for the last few years because of the brain insulin resistance (IR) and dysregulation of insulin signaling in the brain, which can further promote pathological progression of AD. IRS-1/PI3K/Akt insulin signaling pathway disorder and its downstream cascade reaction are responsible for cognitive decline in the brain. In recent years, a growing number of studies has documented that dysregulation of insulin signaling is a key feature of AD and has crucial correlations with serine/tyrosine (Ser/Tyr) phosphorylation of insulin receptor substance-1(IRS-1). Phosphorylation of this protein has been identified as an important molecule involved in the process of amyloid-β (Aβ) deposition into senile plaques (SPs) and tau hyperphosphorylation into neurofibrillary tangles (NFTs). In this paper, we review the links between IRS-1 and the PI3K/Akt insulin signaling pathway, and highlight phosphorylated IRS-1 which negatively regulated by downstream effector of Akt such as mTOR, S6K, and JNK, among others in AD. Furthermore, anti-diabetic drugs including metformin, thiazolidinediones, and glucagon-like peptide-1 (GLP-1) analogue could modulate IRS-1 phosphorylation, brain IR, PI3K/Akt insulin signaling pathway, and other pathologic processes of AD. The above suggest that anti-diabetic drugs may be promising strategies for AD disease-modifying treatments.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aaron MK et al (2017) Effects of the insulin sensitizer metformin in Alzheimer disease pilot data from a randomized placebo-controlled crossover study. Alzheimer Dis Assoc Disord 31:107–113. https://doi.org/10.1097/WAD.0000000000000202
Akhtar A, Sah SP (2020) Insulin signaling pathway and related molecules: role in neurodegeneration and Alzheimer’s disease. Neurochem Int 135:104707. https://doi.org/10.1016/j.neuint.2020.104707
Akhtar A, Bishnoi M, Sah SP (2020a) Sodium orthovanadate improves learning and memory in intracerebroventricular-streptozotocin rat model of Alzheimer’s disease through modulation of brain insulin resistance induced tau pathology. Brain Res Bull 164:83–97. https://doi.org/10.1016/j.brainresbull.2020.08.001
Akhtar A, Dhaliwal J, Saroj P, Uniyal A, Bishnoi M, Sah SP (2020b) Chromium picolinate attenuates cognitive deficit in ICV-STZ rat paradigm of sporadic Alzheimer’s-like dementia via targeting neuroinflammatory and IRS-1/PI3K/AKT/GSK-3β pathway. Inflammopharmacology 28:385–400. https://doi.org/10.1007/s10787-019-00681-7
An J et al (2019) Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5xFAD mouse model of Alzheimer’s disease. Behav Brain Res 370:111932. https://doi.org/10.1016/j.bbr.2019.111932
Apelt J, Mehlhorn G, Schliebs R (1999) Insulin-sensitive GLUT4 glucose transporters are colocalized with GLUT3-expressing cells and demonstrate a chemically distinct neuron-specific localization in rat brain. J Neurosci Res 57:693–705
Arnold SE et al (2018) Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol 14:168–181. https://doi.org/10.1038/nrneurol.2017.185
Arranz AM, De Strooper B (2019) The role of astroglia in Alzheimer’s disease: pathophysiology and clinical implications. Lancet Neurol 18:406–414. https://doi.org/10.1016/s1474-4422(18)30490-3
Athauda D et al (2017) Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664–1675. https://doi.org/10.1016/s0140-6736(17)31585-4
Aviles-Olmos I et al (2013) Exenatide and the treatment of patients with Parkinson’s disease. J Clin Invest 123:2730–2736. https://doi.org/10.1172/JCI68295
Bahrami F, Asgari A, Hosseinmardi N, Janahmadi M (2019) Peroxisome proliferator-activated receptor (PPAR)-gamma modifies abeta neurotoxin-induced electrophysiological alterations in rat primary cultured hippocampal neurons. Iran J Pharm Res 18:1403–1418. https://doi.org/10.22037/ijpr.2019.1100783
Ballard C et al (2020) Drug repositioning and repurposing for Alzheimer disease. Nat Rev Neurol 16:661–673. https://doi.org/10.1038/s41582-020-0397-4
Barini E et al (2016) Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy. Mol Neurodegener 11:16. https://doi.org/10.1186/s13024-016-0082-7
Barone E et al (2016) Impairment of biliverdin reductase-a promotes brain insulin resistance in Alzheimer disease: a new paradigm. Free Radic Biol Med 91:127–142. https://doi.org/10.1016/j.freeradbiomed.2015.12.012
Batista AF et al (2018) The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer’s disease. J Pathol 245:85–100. https://doi.org/10.1002/path.5056
Bazzari FH, Abdallah DM, Elbhar HS (2019) Chenodeoxycholic acid ameliorates AlCl3-induced Alzheimer’s disease neurotoxicity and cognitive deterioration via enhanced insulin signaling in rats. Molecules 24:1992. https://doi.org/10.3390/molecules24101992
Bedse G, Di Domenico F, Serviddio G, Cassano T (2015) Aberrant insulin signaling in Alzheimer’s disease: current knowledge. Front Neurosci 9:204. https://doi.org/10.3389/fnins.2015.00204
Beeri MS, Bendlin BB (2020) The link between type 2 diabetes and dementia: from biomarkers to treatment. Lancet Diabetes Endocrinol 8:736–738. https://doi.org/10.1016/s2213-8587(20)30267-9
Bendlin BB (2019) Antidiabetic therapies and Alzheimer disease. Dialogues Clin Neurosci 21:83–91. https://doi.org/10.31887/DCNS.2019.21.1/bblendin
Bhat R et al (2003) Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 278:45937–45945. https://doi.org/10.1074/jbc.M306268200
Blanchard JW, Tsai LH (2019) Unraveling the paradox of statins with human neurons: new leads in Alzheimer’s disease. Cell Stem Cell 24:347–349. https://doi.org/10.1016/j.stem.2019.02.003
Blumrich EM, Dringen R (2019) Metformin accelerates glycolytic lactate production in cultured primary cerebellar granule neurons. Neurochem Res 44:188–199. https://doi.org/10.1007/s11064-017-2346-1
Boccardi V, Murasecco I, Mecocci P (2019) Diabetes drugs in the fight against Alzheimer’s disease. Ageing Res Rev 54:100936. https://doi.org/10.1016/j.arr.2019.100936
Bomba M et al (2013) Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell Death Dis 4:e612. https://doi.org/10.1038/cddis.2013.139
Bomba M et al (2018) Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice. Neurobiol Aging 64:33–43. https://doi.org/10.1016/j.neurobiolaging.2017.12.009
Bomfim TR et al (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease—associated Aβ oligomers. J Clin Invest 122:1339–1353. https://doi.org/10.1172/JCI57256
Boucher J, Kleinridders A, Kahn CR (2014) Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol 6:a009191. https://doi.org/10.1101/cshperspect.a009191
Butterfield DA, Halliwell B (2019) Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci 20:148–160. https://doi.org/10.1038/s41583-019-0132-6
Candeias E et al (2012) The impairment of insulin signaling in Alzheimer’s disease. IUBMB Life 64:951–957. https://doi.org/10.1002/iub.1098
Cao B et al (2018) Comparative efficacy and acceptability of antidiabetic agents for Alzheimer’s disease and mild cognitive impairment: a systematic review and network meta-analysis. Diabetes Obes Metab 20:2467–2471. https://doi.org/10.1111/dom.13373
Chang KL, Pee HN, Yang S, Ho PC (2015) Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer’s disease. Sci Rep 5:9000. https://doi.org/10.1038/srep09000
Chang KL, Wong LR, Pee HN, Yang S, Ho PC (2019) Reverting metabolic dysfunction in cortex and cerebellum of APP/PS1 mice, a model for alzheimer’s disease by pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist. Mol Neurobiol 56:7267–7283. https://doi.org/10.1007/s12035-019-1586-2
Chatterjee S, Mudher A (2018) Alzheimer’s disease and type 2 diabetes: a critical assessment of the shared pathological traits. Front Neurosci 12:383. https://doi.org/10.3389/fnins.2018.00383
Chaudhari K et al (2020) Determination of metformin bio-distribution by LC-MS/MS in mice treated with a clinically relevant paradigm. PLoS ONE 15:e0234571. https://doi.org/10.1371/journal.pone.0234571
Chen B, Teng Y, Zhang X, Lv X, Yin Y (2016a) Metformin alleviated abeta-induced apoptosis via the suppression of JNK/MAPK signaling pathway in cultured hippocampal neurons. Biomed Res Int 2016:1421430. https://doi.org/10.1155/2016/1421430
Chen Q, Wang YP, Pan XD, Liu XY, Chen Zh, Liu L (2016b) Exendin-4 protects Aβ(1–42) oligomer-induced PC12 cell apoptosis. Am J Transl Res 8:3540–3548 (Collection 2016)
Chen WB, Chen J, Liu ZY, Luo B, Zhou T, Fei EK (2020) Metformin enhances excitatory synaptic transmission onto hippocampal CA1 pyramidal neurons. Brain Sci 10:706. https://doi.org/10.3390/brainsci10100706
Chen Y et al (2021) Metformin attenuates plaque-associated tau pathology and reduces amyloid-beta burden in APP/PS1 mice. Alzheimers Res Ther 13:40. https://doi.org/10.1186/s13195-020-00761-9
Cheng H, Shang Y, Jiang L, Shi TL, Wang L (2016) The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer’s disease and mild-to-moderate Alzheimer’s disease: a meta-analysis. Int J Neurosci 126:299–307. https://doi.org/10.3109/00207454.2015.1015722
Chiang HC, Wang L, Xie Z, Yau A, Zhong Y (2010) PI3 kinase signaling is involved in abeta-induced memory loss in Drosophila. Proc Natl Acad Sci USA 107:7060–7065. https://doi.org/10.1073/pnas.0909314107
Chiu SL, Chen CM, Cline HT (2008) Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron 58:708–719. https://doi.org/10.1016/j.neuron.2008.04.014
Chua LM, Lim ML, Chong PR, Hu ZP, Cheung NS, Wong BS (2012) Impaired neuronal insulin signaling precedes Aβ42 accumulation in female AβPPsw/PS1ΔE9 mice. J Alzheimers Dis 29:783–791. https://doi.org/10.3233/JAD-2012-111880
Copps KD, White MF (2012) Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia 55:2565–2582. https://doi.org/10.1007/s00125-012-2644-8
Daisuke T, Wataru F, Taguchi A (2019) Involvement of insulin receptor substrates in cognitive impairment and Alzheimer’s disease. Neural Regen Res 14:1330–1334. https://doi.org/10.4103/1673-5374.253535
De Felice FG (2013) Alzheimer’s disease and insulin resistance: translating basic science into clinical applications. J Clin Invest 123:531–539. https://doi.org/10.1172/JCI64595
De Strooper B, Karran E (2016) The cellular phase of Alzheimer’s disease. Cell 164:603–615. https://doi.org/10.1016/j.cell.2015.12.056
de la Monte SM (2014) Type 3 diabetes is sporadic Alzheimers disease: mini-review. Eur Neuropsychopharmacol 24:1954–1960. https://doi.org/10.1016/j.euroneuro.2014.06.008
Denner LA et al (2012) Cognitive enhancement with rosiglitazone links the hippocampal PPARgamma and ERK MAPK signaling pathways. J Neurosci 32:16725–16735a. https://doi.org/10.1523/JNEUROSCI.2153-12.2012
Di Domenico F, Tramutola A, Foppoli C, Head E, Perluigi M, Butterfield DA (2018) mTOR in down syndrome: role in Aβ and tau neuropathology and transition to Alzheimer disease-like dementia. Free Radic Biol Med 114:94–101. https://doi.org/10.1016/j.freeradbiomed.2017.08.009
Diehl T, Mullins R, Kapogiannis D (2017) Insulin resistance in Alzheimer’s disease. Transl Res 183:26–40. https://doi.org/10.1016/j.trsl.2016.12.005
Dineley KT, Jahrling JB, Denner L (2014) Insulin resistance in Alzheimer’s disease. Neurobiol Dis 72(Pt A):92–103. https://doi.org/10.1016/j.nbd.2014.09.001
DiTacchio KA, Heinemann SF, Dziewczapolski G (2015) Metformin treatment alters memory function in a mouse model of Alzheimer’s disease. J Alzheimers Dis 44:43–48. https://doi.org/10.3233/JAD-141332
Duarte AI et al (2020) Liraglutide protects against brain amyloid-beta1-42 accumulation in female mice with early Alzheimer’s disease-like pathology by partially rescuing oxidative/nitrosative stress and inflammation. Int J Mol Sci 21:1746. https://doi.org/10.3390/ijms21051746
Dubey SK et al (2020) Insulin mediated novel therapies for the treatment of Alzheimer’s disease. Life Sci 249:117540. https://doi.org/10.1016/j.lfs.2020.117540
Eldar-Finkelman H, Krebs EG (1997) Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc Natl Acad Sci USA 94:9660–9664
Escribano L et al (2010) Rosiglitazone rescues memory impairment in Alzheimer’s transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35:1593–1604. https://doi.org/10.1038/npp.2010.32
Farr SA, Roesler E, Niehoff ML, Roby DA, McKee A, Morley JE (2019) Metformin improves learning and memory in the SAMP8 mouse model of Alzheimer’s disease. J Alzheimers Dis 68:1699–1710. https://doi.org/10.3233/JAD-181240
Femminella GD et al (2019) Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study). Trials 20:191. https://doi.org/10.1186/s13063-019-3259-x
Fernandez AM, Torres-Aleman I (2012) The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci 13:225–239. https://doi.org/10.1038/nrn3209
Fernando RN, Albiston AL, Chai SY (2008) The insulin-regulated aminopeptidase IRAP is colocalised with GLUT4 in the mouse hippocampus–potential role in modulation of glucose uptake in neurones? Eur J Neurosci 28:588–598. https://doi.org/10.1111/j.1460-9568.2008.06347.x
Ferreira ST, Clarke JR, Bomfim TR, De Felice FG (2014) Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer’s disease. Alzheimers Dement 10:S76-83. https://doi.org/10.1016/j.jalz.2013.12.010
Gao S, Duan C, Gao G, Wang X, Yang H (2015) Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling. Int J Biochem Cell Biol 64:25–33. https://doi.org/10.1016/j.biocel.2015.03.006
Garabadu D, Verma J (2019) Exendin-4 attenuates brain mitochondrial toxicity through PI3K/Akt-dependent pathway in amyloid beta (1–42)-induced cognitive deficit rats. Neurochem Int 128:39–49. https://doi.org/10.1016/j.neuint.2019.04.006
Garg G, Singh S, Singh AK, Rizvi SI (2017) Anti-aging effect of metformin on brain in naturally aged and accelerated senescence model of rat. Rejuvenation Res 20:173–182. https://doi.org/10.1089/rej.2016.1883
Gejl M et al (2016) In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci 8:108. https://doi.org/10.3389/fnagi.2016.00108
Gejl M, Brock B, Egefjord L, Vang K, Rungby J, Gjedde A (2017) Blood-brain glucose transfer in Alzheimer’s disease: effect of GLP-1 analog treatment. Sci Rep 7:17490. https://doi.org/10.1038/s41598-017-17718-y
Geldmacher DS, Fritsch T, McClendon MJ, Landreth G (2011) A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 68:45–50. https://doi.org/10.1001/archneurol.2010.229
Gold M et al (2010) Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 30:131–146. https://doi.org/10.1159/000318845
Gourmaud S et al (2015) Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. J Psychiatry Neurosci 40:151–161. https://doi.org/10.1503/jpn.140062
Grillo CA et al (2015) Hippocampal insulin resistance impairs spatial learning and synaptic plasticity. Diabetes 64:3927–3936. https://doi.org/10.2337/db15-0596
Gual P, Le Marchand-Brustel Y, Tanti JF (2005) Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87:99–109. https://doi.org/10.1016/j.biochi.2004.10.019
Gupta A, Dey CS (2012) PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance. Mol Biol Cell 23:3882–3898. https://doi.org/10.1091/mbc.E12-05-0337
Gupta A, Bisht B, Dey CS (2011) Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes. Neuropharmacology 60:910–920. https://doi.org/10.1016/j.neuropharm.2011.01.033
Hancer NJ, Qiu W, Cherella C, Li Y, Copps KD, White MF (2014) Insulin and metabolic stress stimulate multisite serine/threonine phosphorylation of insulin receptor substrate 1 and inhibit tyrosine phosphorylation. J Biol Chem 289:12467–12484. https://doi.org/10.1074/jbc.M114.554162
Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH (1992) Glycogen synthase kinase-3 induces Alzheimer’s disease-like phosphorylation of tau generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 147:58–62. https://doi.org/10.1016/0304-3940(92)90774-2
Hansen HH et al (2015) The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer’s disease. J Alzheimers Dis 46:877–888. https://doi.org/10.3233/JAD-143090
Harrington C et al (2011) Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: two phase 3 studies. Curr Alzheimer Res 8:592–606. https://doi.org/10.2174/156720511796391935
Herschkovitz A, Liu YF, Ilan E, Ronen D, Boura-Halfon S, Zick Y (2007) Common inhibitory serine sites phosphorylated by IRS-1 kinases, triggered by insulin and inducers of insulin resistance. J Biol Chem 282:18018–18027. https://doi.org/10.1074/jbc.M610949200
Hildreth KL et al (2015) Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: a pilot study. Dementia Geriatr Cogn Disord Extra 5:51–63. https://doi.org/10.1159/000371509
Hirosumi J et al (2002) A central role for JNK in obesity and insulin resistance. Nature 420:333–336. https://doi.org/10.1038/nature01137
Horwood JM, Dufour F, Laroche S, Davis S (2006) Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. Eur J Neurosci 23:3375–3384. https://doi.org/10.1111/j.1460-9568.2006.04859.x
Hsu CC, Wahlqvist ML, Lee MS, Tsai HN (2011) Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis 24:485–493. https://doi.org/10.3233/JAD-2011-101524
Hunter K, Hölscher C (2012) Drugs developed to treat diabetes, liraglutide and lixesenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 13:33. https://doi.org/10.1186/1471-2202-13-33
Iketani R, Ohno K, Kawasaki Y, Matsumoto K, Yamada H, Kishino S (2018) Apolipoprotein E gene polymorphisms affect the efficacy of thiazolidinediones for Alzheimer’s disease: a systematic review and meta-analysis. Biol Pharm Bull 41:1017–1023. https://doi.org/10.1248/bpb.b17-00929
Imfeld P, Bodmer M, Jick SS, Meier CR (2012) Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based case-control study. J Am Geriatr Soc 60:916–921. https://doi.org/10.1111/j.1532-5415.2012.03916.x
International AsD (2019) World Alzheimer report 2019: attitudes to dementia.
Jahrling JB, Hernandez CM, Denner L, Dineley KT (2014) PPARgamma recruitment to active ERK during memory consolidation is required for Alzheimer’s disease-related cognitive enhancement. J Neurosci 34:4054–4063. https://doi.org/10.1523/JNEUROSCI.4024-13.2014
Jantrapirom S et al (2020) Liraglutide suppresses tau hyperphosphorylation, amyloid Beta accumulation through regulating neuronal insulin signaling and BACE-1 activity. Int J Mol Sci. https://doi.org/10.3390/ijms21051725
Jaworski T, Banach-Kasper E, Gralec K (2019) GSK-3β at the intersection of neuronal plasticity and neurodegeneration. Neural Plast 2019:4209475. https://doi.org/10.1155/2019/4209475
Jia XT et al (2016) Exendin-4, a glucagon-like peptide 1 receptor agonist, protects against amyloid-beta peptide-induced impairment of spatial learning and memory in rats. Physiol Behav 159:72–79. https://doi.org/10.1016/j.physbeh.2016.03.016
Kapogiannis D et al (2015) Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer’s disease. FASEB J 29:589–596. https://doi.org/10.1096/fj.14-262048
Kellar D, Craft S (2020) Brain insulin resistance in Alzheimer’s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol 19:758–766. https://doi.org/10.1016/s1474-4422(20)30231-3
Khan MA, Alam Q, Haque A, Ashafaq M, Khan MJ, Ashraf GM, Ahmad M (2019) Current progress on peroxisome proliferator-activated receptor gamma agonist as an emerging therapeutic approach for the treatment of Alzheimer’s disease: an update. Curr Neuropharmacol 17:232–246. https://doi.org/10.2174/1570159X16666180828100002
Kleinridders A (2016) Deciphering brain insulin receptor and insulin-like growth factor 1 receptor signalling. J Neuroendocrinol. https://doi.org/10.1111/jne.12433.10.1111/jne.12433
Kleinridders A, Ferris HA, Cai W, Kahn CR (2014) Insulin action in brain regulates systemic metabolism and brain function. Diabetes 63:2232–2243. https://doi.org/10.2337/db14-0568
Kong J, Wan L, Wang Y, Zhang H, Zhang W (2020) Liraglutide attenuates Abeta42 generation in APPswe/SH-SY5Y cells through the regulation of autophagy. Neuropsychiatr Dis Treat 16:1817–1825. https://doi.org/10.2147/NDT.S260160
Lanzerstorfer P, Yoneyama Y, Hakuno F, Muller U, Hoglinger O, Takahashi S, Weghuber J (2015) Analysis of insulin receptor substrate signaling dynamics on microstructured surfaces. FEBS J 282:987–1005. https://doi.org/10.1111/febs.13213
Liberman Z, Eldar-Finkelman H (2005) Serine 332 phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin signaling. J Biol Chem 280:4422–4428. https://doi.org/10.1074/jbc.M410610200
Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX (2008) Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 582:359–364. https://doi.org/10.1016/j.febslet.2007.12.035
Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2011) Deficient brain insulin signalling pathway in Alzheimer’s disease and diabetes. J Pathol 225:54–62. https://doi.org/10.1002/path.2912
Liu J, Wang LN, Jia JP (2015) Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer’s disease and amnestic mild cognitive impairment: a systematic review and meta-analysis. Drugs Aging 32:57–65. https://doi.org/10.1007/s40266-014-0228-7
Liu XY, Wang LX, Chen Z, Liu LB (2016) Liraglutide prevents beta-amyloid-induced neurotoxicity in SH-SY5Y cells via a PI3K-dependent signaling pathway. Neurol Res 38:313–319. https://doi.org/10.1080/01616412.2016.1145914
Lu XY et al (2020) Metformin ameliorates abeta pathology by insulin-degrading enzyme in a transgenic mouse model of Alzheimer’s disease. Oxid Med Cell Longev 2020:2315106. https://doi.org/10.1155/2020/2315106
Luchsinger JA et al (2016) Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial. J Alzheimers Dis 51:501–514. https://doi.org/10.3233/JAD-150493
Ma QL et al (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 29:9078–9089. https://doi.org/10.1523/JNEUROSCI.1071-09.2009
Mandrekar-Colucci S, Karlo JC, Landreth GE (2012) Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease. J Neurosci 32:10117–10128. https://doi.org/10.1523/JNEUROSCI.5268-11.2012
Mao YF et al (2016) Intranasal insulin alleviates cognitive deficits and amyloid pathology in young adult APPswe/PS1dE9 mice. Aging Cell 15:893–902. https://doi.org/10.1111/acel.12498
McClean PL, Holscher C (2014) Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology 76Pt A:57–67. https://doi.org/10.1016/j.neuropharm.2013.08.005
McClean PL, Parthsarathy V, Faivre E, Holscher C (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci 31:6587–6594. https://doi.org/10.1523/JNEUROSCI.0529-11.2011
McClean PL, Jalewa J, Holscher C (2015) Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice. Behav Brain Res 293:96–106. https://doi.org/10.1016/j.bbr.2015.07.024
McNay EC, Recknagel AK (2011) Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol Learn Mem 96:432–442. https://doi.org/10.1016/j.nlm.2011.08.005
Moloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31:224–243. https://doi.org/10.1016/j.neurobiolaging.2008.04.002
Mooradian AD, Chung HC, Shah GN (1997) GLUT-1 expression in the cerebra of patients with Alzheimer’s disease. Neurobiol Aging 18:469–474
Mullins RJ, Diehl TC, Chia CW, Kapogiannis D (2017a) Insulin resistance as a link between amyloid-beta and tau pathologies in Alzheimer’s disease. Front Aging Neurosci 9:118. https://doi.org/10.3389/fnagi.2017.00118
Mullins RJ, Mustapic M, Goetzl EJ, Kapogiannis D (2017b) Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer’s disease. Hum Brain Mapp 38:1933–1940. https://doi.org/10.1002/hbm.23494
Mullins RJ et al (2019) A pilot study of exenatide actions in Alzheimer’s disease. Curr Alzheimer Res 16:741–752. https://doi.org/10.2174/1567205016666190913155950
Munoz-Jimenez M, Zaarkti A, Garcia-Arnes JA, Garcia-Casares N (2020) Antidiabetic drugs in Alzheimer’s disease and mild cognitive impairment: a systematic review. Dement Geriatr Cogn Disord 49:423–434. https://doi.org/10.1159/000510677
Nichols E et al (2019) Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 18:88–106. https://doi.org/10.1016/s1474-4422(18)30403-4
Panagaki T, Michael M, Holscher C (2017) Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells. Sci Rep 7:16158. https://doi.org/10.1038/s41598-017-16488-x
Pardeshi R et al (2017) Insulin signaling: an opportunistic target to minify the risk of Alzheimer’s disease. Psychoneuroendocrinology 83:159–171. https://doi.org/10.1016/j.psyneuen.2017.05.004
Park KM, Bowers WJ (2010) Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal 22:977–983. https://doi.org/10.1016/j.cellsig.2010.01.010
Pasquale P et al (2016) Biological and biophysics aspects of metformin-induced effects cortex mitochondrial dysfunction and promotion of toxic amyloid pre-fibrillar aggregates. Aging (Albany NY). 8:1718–1734. https://doi.org/10.18632/aging.101004
Perluigi M, Di Domenico F, Butterfield DA (2015) mTOR signaling in aging and neurodegeneration: at the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiol Dis 84:39–49. https://doi.org/10.1016/j.nbd.2015.03.014
Perry TA, Lahiri DK, Chen DM, Zhou J, Shaw KTY, Egan JM, Greig N (2002) A novel neutrotrophic property of glucagon-like peptide 1 a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 300:958–966. https://doi.org/10.1124/jpet.300.3.958
Perry TA, Lahiri DK, Sambamurti K, Chen DM, Mattson MP, Egan JM, Greig N (2003) Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 72:603–612. https://doi.org/10.1002/jnr.10611
Prakash A, Kumar A (2014) Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of β-amyloid animal model of Alzheimer’s disease. Neurotox Res 25:335–347. https://doi.org/10.1007/s12640-013-9437-9
Qi L et al (2016) Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3beta pathway in an amyloid beta protein induced alzheimer disease mouse model. Eur J Pharmacol 783:23–32. https://doi.org/10.1016/j.ejphar.2016.04.052
Rahman SO, Panda BP, Parvez S, Kaundal M, Hussain S, Akhtar M, Najmi AK (2019) Neuroprotective role of astaxanthin in hippocampal insulin resistance induced by Abeta peptides in animal model of Alzheimer’s disease. Biomed Pharmacother 110:47–58. https://doi.org/10.1016/j.biopha.2018.11.043
Ribe EM, Lovestone S (2016) Insulin signalling in Alzheimer’s disease and diabetes: from epidemiology to molecular links. J Intern Med 280:430–442. https://doi.org/10.1111/joim.12534
Risner ME et al (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J 6:246–254. https://doi.org/10.1038/sj.tpj.6500369
Rotermund C, Machetanz G, Fitzgerald JC (2018) The therapeutic potential of metformin in neurodegenerative diseases. Front Endocrinol (Lausanne) 9:400. https://doi.org/10.3389/fendo.2018.00400
Salameh TS, Rhea EM, Talbot K, Banks WA (2020) Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics. Biochem Pharmacol 180:114187. https://doi.org/10.1016/j.bcp.2020.114187
Salcedo-Tello P, Ortiz-Matamoros A, Clorinda A (2011) GSK3 function in the brain during development, neuronal plasticity, and neurodegeneration. Int J Alzheimers Dis 2011:189728. https://doi.org/10.4061/2011/189728
Samuel VT, Shulman GI (2012) Mechanisms for insulin resistance: common threads and missing links. Cell 148:852–871. https://doi.org/10.1016/j.cell.2012.02.017
Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2011) Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32:1626–1633. https://doi.org/10.1016/j.neurobiolaging.2009.10.009
Searcy JL et al (2012) Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer’s disease. J Alzheimers Dis 30:943–961. https://doi.org/10.3233/JAD-2012-111661
Shah OJ, Wang Z, Hunter T (2004) Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14:1650–1656. https://doi.org/10.1016/j.cub.2004.08.026
Solmaz V, Cinar BP, Yigitturk G, Cavusoglu T, Taskiran D, Erbas O (2015) Exenatide reduces TNF-alpha expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. Eur J Pharmacol 765:482–487. https://doi.org/10.1016/j.ejphar.2015.09.024
Spinelli M, Fusco S, Grassi C (2020) Brain insulin resistance impairs hippocampal plasticity. Vitam Horm 114:281–306. https://doi.org/10.1016/bs.vh.2020.04.005
Stanley M, Macauley SL, Holtzman DM (2016) Changes in insulin and insulin signaling in Alzheimer’s disease: cause or consequence? J Exp Med 213:1375–1385. https://doi.org/10.1084/jem.20160493
Steen E et al (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—is this type 3 diabetes. J Alzheimers Dis 7:63–80. https://doi.org/10.3233/jad-2005-7107
Talbot K (2014) Brain insulin resistance in Alzheimer’s disease and its potential treatment with GLP-1 analogs. Neurodegener Dis Manag 4:31–40. https://doi.org/10.2217/nmt.13.73
Talbot K, Wang HY (2014) The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer’s disease. Alzheimers Dement 10:S12-25. https://doi.org/10.1016/j.jalz.2013.12.007
Talbot K et al (2012) Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122:1316–1338. https://doi.org/10.1172/JCI59903
Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7:85–96. https://doi.org/10.1038/nrm1837
Tramutola A et al (2015) Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD. J Neurochem 133:739–749. https://doi.org/10.1111/jnc.13037
Tremblay F et al (2007) Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci USA 104:14056–14061
Tseng CH (2018) Pioglitazone reduces dementia risk in patients with type 2 diabetes mellitus: a retrospective cohort analysis. J Clin Med. https://doi.org/10.3390/jcm7100306
Tseng CH (2019) Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients. Aging (Albany NY) 11:2724–2734. https://doi.org/10.18632/aging.101944
Tze PN, Liang F, Keng BY, Tih ShL, Chay HT, Winblad B (2014) Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis 41:61–68. https://doi.org/10.3233/JAD-131901
Tzimopoulou S et al (2010) A multi-center randomized proof-of-concept clinical trial applying [(1)(8)F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer’s disease. J Alzheimers Dis 22:1241–1256. https://doi.org/10.3233/JAD-2010-100939
Van der Heide LP, Kamal A, Artola A, Gispen WH, Ramakers GM (2005) Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-d-aspartate receptor and phosphatidyl-inositol-3-kinase-dependent manner. J Neurochem 94:1158–1166. https://doi.org/10.1111/j.1471-4159.2005.03269.x
Velazquez R, Tran A, Ishimwe E, Denner L, Dave N, Oddo S, Dineley KT (2017) Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer’s disease. Neurobiol Aging 58:1–13. https://doi.org/10.1016/j.neurobiolaging.2017.06.003
Wallach JD et al (2020) Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ (Clin Res ed) 368:l7078. https://doi.org/10.1136/bmj.l7078
Wang X, Wang L, Jiang R, Xu Y, Zhao X, Li Y (2016) Exendin-4 antagonizes Abeta1-42-induced attenuation of spatial learning and memory ability. Exp Ther Med 12:2885–2892. https://doi.org/10.3892/etm.2016.3742
Watson GS et al (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry 13:950–958. https://doi.org/10.1176/appi.ajgp.13.11.950
Weller J, Budson A (2018) Current understanding of Alzheimer's disease diagnosis and treatment. F1000Res 7 doi:https://doi.org/10.12688/f1000research.14506.1
White MF (2003) Insulin signaling in health and disease. Science 302:1710–1711
Wong LR, Wong P, Ho PC (2020) Metabolic profiling of female Tg2576 mouse brains provides novel evidence supporting intranasal low-dose pioglitazone for long-term treatment at an early stage of Alzheimer’s disease. Biomed. https://doi.org/10.3390/biomedicines8120589
Yan X, Hu Y, Wang B, Wang S, Zhang X (2020) Metabolic dysregulation contributes to the progression of Alzheimer’s disease. Front Neurosci 14:530219. https://doi.org/10.3389/fnins.2020.530219
Yarchoan M, Arnold SE (2014) Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 63:2253–2261. https://doi.org/10.2337/db14-0287
Yarchoan M et al (2014) Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer’s disease and tauopathies. Acta Neuropathol 128:679–689. https://doi.org/10.1007/s00401-014-1328-5
Yoon SO et al (2012) JNK3 perpetuates metabolic stress induced by Aβ peptides. Neuron 75:824–837. https://doi.org/10.1016/j.neuron.2012.06.024
Zhang X, Tang S, Zhang Q, Shao W, Han X, Wang Y, Du Y (2016) Endoplasmic reticulum stress mediates JNK-dependent IRS-1 serine phosphorylation and results in Tau hyperphosphorylation in amyloid beta oligomer-treated PC12 cells and primary neurons. Gene 587:183–193. https://doi.org/10.1016/j.gene.2016.05.018
Zhang J, Chen C, Hua S, Liao H, Wang M, Xiong Y, Cao F (2017) An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer’s disease. Diabetes Res Clin Pract 124:41–47. https://doi.org/10.1016/j.diabres.2016.10.024
Zhou Q et al (2015) Inhibition of c-Jun N-terminal kinase activation reverses Alzheimer disease phenotypes in APPswe/PS1dE9 mice. Ann Neurol 77:637–654. https://doi.org/10.1002/ana.24361
Zhu Y, Shan X, Yuzwa SA, Vocadlo DJ (2014) The emerging link between O-GlcNAc and Alzheimer disease. J Biol Chem 289:34472–34481. https://doi.org/10.1074/jbc.R114.601351
Zick Y (2005) Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci STKE 2005:pe4. https://doi.org/10.1126/stke.2682005pe4
Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci 12:723–738. https://doi.org/10.1038/nrn3114
Acknowledgements
The authors would like to thank the National Natural Science Foundation of China (NO.81573927) and The Scientific Research and Graduate Training Project of Beijing Municipal Commission of Education (2016, 2017) for providing support.
Author information
Authors and Affiliations
Contributions
MCZ designed and wrote the manuscript. PWW critically reviewed the manuscript and did the required editing and supervision.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest in the preparation of manuscript.
Rights and permissions
About this article
Cite this article
Zheng, M., Wang, P. Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer’s disease. 3 Biotech 11, 179 (2021). https://doi.org/10.1007/s13205-021-02738-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13205-021-02738-3